Lundbeck’s Amlenetug Receives FDA Fast Track for Multiple System Atrophy
Denmark-based pharma company Lundbeck A/S (VIE: LUNB) has announced that it has received Fast Track...
OnCusp Therapeutics’ CUSP06 Receives FDA Fast Track for Ovarian Cancer
Sino-US company OnCusp Therapeutics Inc. has announced that it has received Fast Track Designation (FTD)...
J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...
Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management
The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...
Astellas Pharma’s Izervay Gets FDA Approval for GA Treatment Without Dosing Limit
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the US Food and Drug Administration...
Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake
China-based Andon Health Co., Ltd (SHE: 002432) announced a plan to obtain the 20% stake...
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...
Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...
Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval
China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...